Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
AZD8233 / Ionis, AstraZeneca
(PDF) AZD8233 antisense oligonucleotide targeting PCSK9 does not ...
AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT ...
AZD8233 | PCSK9 siRNA | MedChemExpress
AZD8233 sodium | PCSK9 siRNA | MedChemExpress
AZD8233 reduced low-density lipoprotein cholesterol levels by 73% in ...
AZD8233 reduced low-density lipoprotein cholesterol levels by 73% | The ...
AstraZeneca’s AZD8233 Shows Positive Results for Hypercholesterolemia
Proposed biotransformation pathways of AZD8233. Metabolite profiling ...
In Vivo Metabolite Profiles of an N-Acetylgalactosamine–Conjugated ...
AI辅助一半小分子药物开发，阿斯利康公布最新研发管线（附PPT）_腾讯新闻
PCSK9丨阿斯利康AZD8233商业化道路崎岖 近日， 阿斯利康 公布了其靶向PCSK9抑制剂AZD8233（ION 449）在 ...
精准、长效、安全，小干扰核酸降脂药物最新研究一文读懂！_降低_mg_水平
Abstract 9747: Safety, Pharmacokinetics and Pharmacodynamics of ...
Table 1 from In Vivo Metabolite Profiles of a GalNAc Conjugated ...
(PDF) In Vivo Metabolite Profiles of a GalNAc Conjugated Antisense ...
An oral antisense oligonucleotide for PCSK9 inhibition | Science ...
AZD8233: a liver-targeted antisense oligonucleotide | American Society ...
MNC药企纷纷布局：口服PCSK9抑制剂的时代或将来临 - 知乎
PCSK9: 心血管疾病治疗的明星靶点 - 知乎
AZD8233在ETESIAN IIb期试验中使高危高胆固醇血症患者的低密度脂蛋白胆固醇水平降低了73%医药新闻-ByDrug-一站式医药资源 ...
口服PCSK9抑制剂，有戏了？阿斯利康发布PCSK9反义疗法最新研究成果 | Science子刊 - 知乎
What are PCSK9 inhibitors and how do you quickly get the latest ...
Quantitative relationship between PCSK9 and LDL‐C. Mean digitized ...
罕见病信息网
AZD0780 | Inhibitor | TargetMol
Writing your introduction | PPTX
剑指心血管疾病——小核酸药物(二)|心血管疾病|胆固醇|核酸|药物|靶向|-健康界
新型 PCSK9 反义寡核苷酸的群体药代动力学,British Journal of Clinical Pharmacology - X-MOL
Table 1 from Identification of GalNAc-Conjugated Antisense ...
AD8232芯片电路Auto Designer设计与构建-CSDN博客
34S-SIL of PCSK9-Active Oligonucleotide as Tools for Accurate ...
PCSK9竞争格局：单抗、siRNA、小分子、CRISPR PCSK9的药物研发竞争充满了故事性......二十世纪70年代，他汀药物的发现为 ...
阿斯利康下一代 PCSK9 抑制剂国内启动临床_Insight_水平_降低
PCSK9 | 前蛋白转化酶/枯草溶菌素9 | 抑制剂 | MCE
中金：核酸药物，时代已至_凤凰网
Population pharmacokinetics of a novel PCSK9 antisense oligonucleotide ...
美国FDA批准阿斯利康哮喘按需治疗急救药物Airsupra|药物|批准|治疗|试验|-健康界
Препарат от холестерина от AstraZeneca и Ionis не перейдет в фазу 3 КИ ...
AstraZeneca's next-generation PCSK9 inhibitor in limbo after latest mid ...
降脂新靶点PCSK9 - 知乎
信达完成国内首报，PCSK9单抗进退两难|PCSK9|胆固醇血症|首报|信达|国内|单抗|药物|水平|汀类|患者|安进|降低|上市|-健康界
信达/康方/君实之后，恒瑞PCSK9单抗获批上市，对垒原研 PCSK9丨快讯 恒瑞 生物丨瑞卡西单抗注射液2025年1月10日，NMPA官网 ...
中金：核酸药物，时代已至_临床
Advances in Oral Biomacromolecule Therapies for Metabolic Diseases - PMC
(PDF) Population pharmacokinetics of a novel PCSK9 antisense ...
梁春教授：ASCVD的精准靶向调脂治疗：离我们有多远？-医谱
2022 年 8 月药企「弹药填充」榜单出炉！
口服PCSK9抑制剂，有戏了？【阿斯利康】发布PCSK9反义疗法最新研究成果 | Science子刊 PCSK9（前蛋白转化酶枯草杆菌蛋白酶 ...
Familial Hypercholesterolemia: JACC Focus Seminar 4/4 | JACC
阿斯利康：1类化药AZD5718片报临床，用于冠状动脉疾病|AZD|FLAP|冠状动脉|白三烯|临床|-健康界
Amgen eyes swift move to ph3 for cardiovascular drug olpasiran ...
AD9833BRMZ中文资料_最新报价_数据手册下载_ADI(亚德诺)-直接数字频率合成(DDS)-立创商城
Targeting PCSK9 as a key player in lipid metabolism: exploiting the ...
AstraZeneca, Ionis drop hypercholesterolemia candidate despite positive ...
Familial Hypercholesterolemia: JACC Focus Seminar 4/4 | Journal of the ...
速递 | 降低坏胆固醇73%，反义寡核苷酸疗法2b期临床结果积极_康德_剂量_治疗
Tissue pharmacokinetics of antisense oligonucleotides: Molecular ...
Antisense Oligonucleotide Therapies
Iqrar Ansari on LinkedIn: Article No. 107 Title: Benzimidazole and ...
AstraZeneca shares positive results for its drug to lower cholesterol
信达生物PCSK-9抑制剂获批上市，国产化进程加速 - 知乎
AstraZeneca dumps Ionis drug despite hit in phase 2 cholesterol trial ...
[단독] 새로운 고콜레스테롤혈증 치료제 ‘ION449’ 2상에서 효능 입증 - 헬스코리아뉴스
AstraZeneca shuts the PhIII door for Ionis’ PCSK9 drug despite positive ...
靶向PCSK9！阿斯利康/Ionis公司反义寡核苷酸疗法在中国获批临床 @药明康德 内容团队报道今日（3月10日），中国国家药监局药品审评中心 ...
PCSK9抑制劑：有效降低LDL膽固醇的創新療法 | 萬灃國際有限公司
PCSK9 反义寡核苷酸疗法！阿斯利康降脂药国内获批临床_Insight_药物_胆固醇
“开门红”小核酸时代将开启？热门靶点、国内企业管线布局早知道|适应症|罕见病|核酸|布局|企业|热门|-健康界
(PDF) A Case Study of Model-Informed Drug Development of a Novel PCSK9 ...
Oligonucleotide
AZ-아이오니스, 'PCSK9 ASO' 2b상 “LDL-C 최대79%↓” - 바이오스펙테이터
Antisense Oligonucleotide-Based Therapy of Viral Infections
PCSK9单抗丨信达，康方，君实获批上市，集齐三家，对垒原研 PCSK9除了获批上市的依洛尤单抗（evolocumab）和阿利西尤单抗 ...
CAS No.93550-62-0 | chem960.com
阿斯利康放弃在美国申报新冠疫苗，终止多个项目开发医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
